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are  rare  autosomal  recessive  conditions  caused  by muta-
tions  in  the HEXB  (Sandhoff  disease), HEXA  (Tay-Sachs 
disease), or GM2A (GM2 activator deficiency) genes. The 
HEXA  and  HEXB  genes  code  for  the  -hexosaminidase  
(-N-acetyl-D-hexosaminidase,  EC  3.2.1.52)   and   sub-
units,  respectively, which dimerize  to  form  the  three  iso-






due, mutations  that  inactivate any of  these  three genes 
Abstract Sandhoff disease, one of the GM2 gangliosidoses, 
is a lysosomal storage disorder characterized by the absence 
of -hexosaminidase A and B activity and the concomitant 
lysosomal accumulation of its substrate, GM2 ganglioside. It 
features catastrophic neurodegeneration and death in early 
childhood. How the lysosomal accumulation of ganglioside 
might affect the early development of the nervous system is 
not understood. Recently, cerebral organoids derived from 
induced pluripotent stem (iPS) cells have illuminated early 
developmental events altered by disease processes. To de-
velop an early neurodevelopmental model of Sandhoff dis-
ease, we first generated iPS cells from the fibroblasts of an 
infantile Sandhoff disease patient, then corrected one of the 
mutant HEXB alleles in those iPS cells using CRISPR/Cas9 
genome-editing technology, thereby creating isogenic con-
trols. Next, we used the parental Sandhoff disease iPS cells 
and isogenic HEXB-corrected iPS cell clones to generate 
cerebral organoids that modeled the first trimester of neuro-
development. The Sandhoff disease organoids, but not the 
HEXB-corrected organoids, accumulated GM2 ganglioside 
and exhibited increased size and cellular proliferation 
compared with the HEXB-corrected organoids.  Whole-
transcriptome analysis demonstrated that development was 
impaired in the Sandhoff disease organoids, suggesting that 
alterations in neuronal differentiation may occur during 
early development in the GM2 gangliosidoses.—Allende,  
M. L.,  E.  K. Cook,  B. C.  Larman, A. Nugent,  J. M.  Brady,  
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remitting  neurodegenerative  diseases  with  hypotonia, 
seizures, macrocephaly,  blindness,  and  progressive  loss 
of  motor  function  and  cognition.  Onset  occurs  by  6 






tile  patients,  the  Sandhoff  disease  mice  store  abundant 
GM2 ganglioside in the nervous system, show progressive 
neurodegeneration, and have a severely shortened lifespan 
(4).  During  the  disease  course,  neuroinflammation  is 
prominent, with monocytic infiltration and significant glio-
sis. Late in the disease, neuronal death occurs by apoptosis 
(5–7).  Whereas  the  acute  neurodegenerative  manifesta-
tions of the disease are believed to be primarily the result of 





Little  is  known  about  early  brain  development  in  the 
GM2 gangliosidoses because of the general inaccessibility 
of human fetal tissue for study. However, probing human 
disease  progression  during  development  is  now  possible 
with  the  reprogramming  of  patient-derived  somatic  cells 
into induced pluripotent stem (iPS) cells and their further 
differentiation into cerebral organoids; three-dimensional 
cell-culture models  of  early  brain  development  (11,  12). 
These systems recapitulate the complex cellular behaviors 
of  the developing brain, allowing  for  the  study of  funda-
mental neurodevelopmental mechanisms, such as growth 




from  the  fibroblasts  of  an  infantile  Sandhoff  disease  pa-
tient. In addition, we generated isogenic iPS cells in which 
we  corrected  the  disease-causing  HEXB  mutation  using 
CRISPR/Cas9 genome editing. We then used the Sandhoff 
disease and control HEXB-corrected iPS cells  to generate 
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profile of the cerebral organoids mirrored that observed in 
fetal neurodevelopment during the first trimester of preg-
nancy.  The  Sandhoff  disease  organoids,  which  accumu-
lated  GM2  ganglioside,  exhibited  an  enlarged  size  with 
increased cellular proliferation, and a gene expression pat-
tern  indicating  impaired differentiation, when compared  





Sandhoff disease infantile patient
The  Sandhoff  disease  patient  included  in  this  study  was  



























stem  cells  (OCT4,  SOX2,  and  SSEA-4),  and were  able  to  form 















single-guide RNA (sgRNA)  containing  a  20 bp  target  sequence 
corresponding to  the 3′ end of  intron 10 and the 5′ portion of 
exon 11 of the human HEXB gene, 5′ GTAACGTTAATGGCTT-
GCGC  3′,  which  was  followed  by  a  protospacer  adjacent motif 
(PAM)  sequence, NGG. The  sgRNA  forward  (5′ GTAACGTTA-
ATGGCTTGCGC 3′) and reverse (5′ GCGCAAGCCATTAACGT-
TAC 3′) sequence oligonucleotides were annealed, phosphorylated, 
and  subcloned  into  the  CRISPR/Cas9  plasmid  pSpCas9(BB)- 
2A-Puro (15) to create the SD/pSpCas9(BB)-2A-Puro plasmid. 
pSpCas9(BB)-2A-Puro (PX459) was a gift from Feng Zhang (Ad-
























acceptor  splice-site mutation was  amplified  by  PCR using  the 
























Generation of cerebral organoids from iPS cells
Cerebral organoids were generated using parental Sandhoff 
disease iPS cells and HEXB-corrected iPS cells according to the 
protocol designed by Lancaster  and  colleagues  (12,  18), with 
the following modification on embryo body formation. Embryo 
bodies  were  generated  on  AggreWell  400  plates  (StemCell 
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GD3,  clone  R24  (mouse  monoclonal  IgG3,  catalog  number 
ab11779;  Abcam,  Cambridge,  MA);  anti-galactosylceramide, 
clone mGalC (mouse monoclonal IgG3, catalog number MAB342; 
Sigma-Aldrich); anti-myelin basic protein (rabbit polyclonal IgG, 


















For  cholera  toxin  B  subunit  staining,  frozen  organoid  sections 
were fixed in cold acetone for 10 min at 20°C, air-dried, blocked 
with 5% normal goat serum in PBS for 1 h at room temperature, 
and  then  incubated with FITC-conjugated cholera  toxin B  sub-
unit  (Sigma-Aldrich)  for 45 min at  room  temperature. Fluores-





by  labeling  with  5-bromo-2-deoxyuridine  (BrdU)  (Thermo 
Fisher Scientific) for 4 h in culture. The cells that incorporated 
BrdU were  detected  using Alexa  Fluor  488-labeled  anti-BrdU 
antibody (A23210; Molecular Probes, Thermo Fisher Scientific) 
according to the manufacturer’s protocol. Fluorescently stained 
sections  were  mounted  and  examined  on  a  confocal  laser- 
scanning microscope as described above. Ten fields per organoid 
section were examined, and the percentage of BrdU+ DAPI+ nu-






manufacturer’s  manual.  Fluorescently  stained  samples  were 
mounted  and  examined  on  a  confocal  laser-scanning  micro-
scope as described above. Ten fields per iPS cell type were ex-
amined,  and  the  percentage  of  EdU+  DAPI+  nuclei  was 
quantified.
Cell apoptosis within organoids was detected by in situ TUNEL 






Transmission  electron  microscopy  of  postmortem  human 
brain and cerebral organoids was performed as described (21).


































infancy developmental  stages  (obtained  from  the Allen Brain 
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Genes that were expressed at levels RPKM >3 in both cerebral 
organoids and brain samples were included for Pearson correlation 



















Creation of isogenic control (HEXB-corrected) iPS cells 









mutations  found  on  each  allele  of  the  gene,  fibroblasts 
from the patient showed nearly absent -hexosaminidase 
activity (Fig. 1C).
Electron microscopy analysis of  frontal  lobe and  thala-
mus samples obtained from the postmortem brain of the 




The  patient  also  exhibited  the  characteristic  macro-



























-hexosaminidase  activity  were  further  analyzed  by  se-
quencing.  Three  of  these  selected  clones  were  found  to 
have correct editing of the HEXB gene based on the repair 
oligodeoxynucleotide sequence and were named isogenic 
HEXB-corrected  clones 1,  2,  and 3. The  three  clones  ex-






corrected  clones  and  none  were  found  to  be  modified 
(supplemental Table S2).




been  used  to  model  normal  human  brain  development 
and disease (11, 12, 23, 27, 28). To determine whether 
-hexosaminidase  deficiency  affects  early  neurodevelop-
ment,  we  generated  cerebral  organoids  from  Sandhoff 








ganoid  frozen  sections,  and  found  the presence of GM2 
ganglioside as early as at week 4 of culture, mainly in cells 
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different  between  Sandhoff  disease  and HEXB-corrected 
organoids at 4 weeks (Fig. 4C, D).
Galactosylceramide,  a  major  glycosphingolipid  of  my-
elin (32), was probed by  immunostaining 10 week Sand-
hoff  and  isogenic  HEXB-corrected  organoid  frozen 
sections  (Fig. 5A,  C).  Expression  of  galactosylceramide, 




production was  not  disturbed  in  the  Sandhoff  disease 
organoids.
Sandhoff disease cerebral organoids are enlarged and 
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analysis  showed  that  Sandhoff  disease  organoids  were  












































stained with DAPI  (left),  anti-GM2 ganglioside  (cen-
ter),  and  anti-3  tubulin  (right).  Representative  im-
ages of entire organoid sections are shown. The insets 
show  higher  magnification  views  of  GM2  staining 
(center) and DAPI, GM2 and 3 tubulin merged stain-
ing  (right).  B: Quantification  of GM2  ganglioside  
expression  in  SD  organoids  (red  bars)  and  isogenic 
HEXB-corrected organoids (white bars)  from week 4 
up to week 10 of culture. GM2 expression was calcu-










 at Univ of M
assachusetts M











Supplemental Material can be found at:














ease  and  isogenic HEXB-corrected  organoids  at  8  weeks 




























Here,  we  describe  an  analysis  of  infantile  Sandhoff  
 at Univ of M
assachusetts M











Supplemental Material can be found at:
558 Journal of Lipid Research Volume 59, 2018




Size  comparison  of  Sandhoff  disease  (SD;  red  bars) 
and  isogenic HEXB-corrected organoids (white bars) 
at week 4 and week 10 of culture performed by calcu-
lating  the  perimeter  of  each  organoid  using  ImageJ 
software.  The  bars  represent mean perimeter  values 
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cordance with  the  results  obtained here with  cerebral 
organoids.
Cerebral organoids have been shown to mimic clinical 




patient  from  whom  the  iPS  cells  were  derived  for  this 
study exhibited megalencephaly, a general feature of GM2 
gangliosidosis  patients.  The  Sandhoff  disease  organoids 
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Fig. 8.  Sandhoff disease  cerebral organoids display 
increased proliferation. A: Proliferation of cells in or-
ganoids. Quantification of  the percentages of BrdU+ 


















were  significantly  larger  in  size  than  the  isogenic HEXB-





sis-associated megalencephaly  in patients; however,  if  the 
proliferative defect extended into the postnatal period, 
it could be clinically  impactful. Further  studies will be 
required  to  clarify whether  there  is  a  causal  relationship 
between  the  increased  proliferation  within  the  Sandhoff 




opment  were  altered  in  the  cerebral  organoids  derived 
from the Sandhoff disease  iPS cells compared with those 





ings  suggest  that  neuronal  differentiation  is  impeded  in 
Sandhoff disease, and are in accordance with work in the 









sphingolipids,  which  are  substantially  increased  in  the 
GM2 gangliosidoses, are known to influence growth and 
differentiation  of  cells  in  a  variety  of  experimental  con-
texts (32, 52–55). The accrual of gangliosides can directly 
promote neural  stem  cell  proliferation  (56–58)  and has 
been implicated in neuronal differentiation (30, 59–63). 
A variety of mechanisms have been described for the influ-






out  the  possibility  that  a  substrate  of  -hexosamindase 
other than GM2 ganglioside (Fig. 1A) may influence cel-
lular  proliferation  and  differentiation  within  cerebral 
organoids.
Early  neurodevelopmental  processes  are  believed  to 
have  little  impact on the major acute symptoms of Sand-
hoff disease (8). This conclusion was reached using an in-
ducible  adult  mouse  model  of  Hexb  deficiency  whose 
disease severity was indistinguishable from a germline defi-
ciency (8). Indeed, within the Sandhoff disease organoids, 
we  did not  observe  an  elevation  of  apoptosis,  which  is  a 
major  factor  in  the  terminal  neurodegenerative  disease 
course. However, the results revealing an altered prolifera-
tion and neuronal differentiation  status exhibited by  the 
Sandhoff  disease  organoids  raise  the  possibility  of  more 
subtle  neurodevelopmental  abnormalities  that  might  be 
masked  by  the  severe  stereotypical  features  of  the  GM2 
gangliosidoses.
The  three-dimensional  cerebral  organoid  model  of 
Sandhoff  disease  provides  a  new  means  to  study  the 
early developmental consequences of lysosomal gangli-
oside storage within a human context. Using this para-
digm,  alterations  in  fundamental  cellular  behaviors, 
proliferation and neuronal differentiation, were identi-
fied, which raise  the possibility  that  they could  impact 
fetal brain development in GM2 gangliosidosis patients. 
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